合并心房纤颤的急性冠脉综合征患者的临床特征及支架置入术后不同抗栓方案比较

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (544 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the efficacy and safety of different antithrombotic therapies in patients after coronary stent implantation through follow-up.Methods The cross-sectional observation study enrolled 1674 ACS patients who had undergone PCI in our hospital. According complications with (n=78) or without (n=1596) atrial fibrillation, these patients were divided into two groups and their clinical manifestations were compared. We followed up 54 patients with CHA₂DS₂-VASc≥2 in the group combined with atrial fibrillation for one year. According to the antithrombotic regimens, these patients were divided into warfarin group(n=19) or non-warfarin group(n=35). SPSS 19.0 was used for statistical analysis.Results The rate of triple vessel lesion was higher in the group combined with atrial fibrillation, and the incidence of death during the in-hospital period(12.8% vs 1.8%, P0.001) was significantly higher than in the group without atrial fibrillation. During the follow-up, significantly more proton pump inhibitors (PPIs) were used in warfarin group than in non-warfarin group (100% vs 51.7%, P0.001). The incidence of minimal bleeding in warfarin group was higher than in non-warfarin group (21.1% vs 2.9%, P=0.028).Conclusions Triple antithrombotic therapy is recommended for patients with ACS after coronary stent implantation. Proper use of PPI may achieve good efficacy and safety.

Key words： atrial fibrillation acute coronary syndrome coronary stent implantation antithrombotic therapy bleeding

Received: 20 August 2017

ZTFLH:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIAN Hao

Cite this article:

QIAN Hao. Clinical manifestations of acute coronary syndrome patients combined with atrial fibrillation and comparison of different antithrombotic therapies after coronary stent implantation[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(12): 1253-1255.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I12/1253

[1]	Hylek E M, Go A S, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation[J]. N Engl J Med, 2003, 349(11) 1019-1026.
[2]	李燕红,武云涛,陈艳梅,等. 华法林对高龄非瓣膜病性心房纤颤患者抗栓治疗的安全性比较[J].武警医学, 2009, 20(10):888-890.
[3]	田东华,王永红,季康. 冠状动脉疾病患者炎性介质与心心房纤颤动的相关性研究[J]. 武警医学, 2013, 24(1) 50-53.
[4]	Marte T, Saely C H, Schmid F, et al. Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography[J]. Am J Cardiol, 2009,103(1)36-40.
[5]	Kay W H, Ivanov J, Freixa X,et al. Antithrombotic therapy after coronary dtenting in patients with nonvalvular atrial fibrillation[J].Canadian J Cardio, 2013, 29(2) 213-218.
[6]	Ruff C T, Giugliano R P, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation a meta-analysis of randomised trials[J]. Lancet,2014, 383(9921)955-962.
[7]	Mega J L, Braunwald E, Wiviott S D, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J].N Engl J Med, 2012,366(1)9-19.
[8]	Oldgren J, Budaj A, Granger C B, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy a randomized, double-blind, phase II trial[J].Eur Heart J, 2011, 32(22)2781-2789.
[9]	Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding[J].J Invasive Cardiol, 2006, 18(4)162-164.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 720-722.